BIOX Bioceres Crop Solutions Corp Forecast, Technical & Fundamental Analysis
Bioceres Crop Solutions Corp is a fully integrated provider of crop productivity solutions, including seeds, seed traits, seed treatments, biologicals, high-value adjuvants, and fertilizers... Show more
BIOX is expected to report earnings to fall 61.83% to -5 cents per share on September 03
Q2'26
Est.
$-0.06
Q1'26
Missed
by $0.11
Q4'25
Missed
by $0.15
Q3'25
Missed
by $0.15
Q2'25
Missed
by $0.78
The last earnings report on May 11 showed earnings per share of -15 cents, missing the estimate of -5 cents. With 670.07K shares outstanding, the current market capitalization sits at 28.14M.
A.I. Advisor
published General Information
General Information
a manager of investments in agricultural biotechnology
A.I.dvisor tells us that BIOX and FMC have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOX and FMC's prices will move in lockstep.
BIOX's Stochastic Oscillator remains in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BIOX moved out of overbought territory on August 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIOX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BIOX broke above its upper Bollinger Band on August 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on BIOX as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
BIOX moved above its 50-day moving average on August 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BIOX crossed bullishly above the 50-day moving average on August 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where BIOX advanced for three days, in of 234 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 114 cases where BIOX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BIOX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.416) is normal, around the industry mean (1.518). BIOX's P/E Ratio (194.850) is considerably higher than the industry average of (44.382). Projected Growth (PEG Ratio) (1.236) is also within normal values, averaging (1.249). BIOX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.040). BIOX's P/S Ratio (0.095) is slightly lower than the industry average of (1.482).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIOX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
